Experienced in Systemic Sclerosis (SSc)

Dr. Tauseef G. Syed

Rheumatology
Greensboro Medical Associates, P.A.
1511 Westover Ter, Suite 201, 
Greensboro, NC 
Accepting New Patients
Offers Telehealth
Experienced in Systemic Sclerosis (SSc)
Greensboro Medical Associates, P.A.
1511 Westover Ter, Suite 201, 
Greensboro, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Tauseef Syed is a Rheumatologist in Greensboro, North Carolina. Dr. Syed is rated as an Experienced provider by MediFind in the treatment of Systemic Sclerosis (SSc). Her top areas of expertise are Polymyositis, Rheumatoid Arthritis (RA), Undifferentiated Connective Tissue Disease (UCTD), and Psoriatic Arthritis. Dr. Syed is currently accepting new patients.

Her clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in OH
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

GREENSBORO MEDICAL ASSOCIATES, P.A.
1511 Westover Ter, Suite 201, Greensboro, NC 27408

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Other
Study Drug: VIB7734
Study Phase: Phase 2
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials
Similar Doctors
Ankoor Shah
Distinguished in Systemic Sclerosis (SSc)
Dr. Ankoor Shah
Rheumatology
Distinguished in Systemic Sclerosis (SSc)
Dr. Ankoor Shah
Rheumatology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (49.6 miles away)
919-684-8111
Experience:
20+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

My primary clinical and research focus is systemic sclerosis (Scleroderma), a rare, chronic autoimmune condition. I direct the Duke Scleroderma Center, one of 40 centers in the country focusing on this disease. We are currently conducting clinical trials and have initiated a registry for patients with scleroderma to help identify better treatments. We utilize a multidisciplinary approach along with pulmonologists, cardiologists, gastroenterologists and hematologists to find the best treatment course for an individual patient. Outside of the hospital I enjoy running and spending time with my family, including our wide assortment of animals. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Systemic Sclerosis (SSc), Scleroma, Scleroderma, and Localized Scleroderma.

Advanced in Systemic Sclerosis (SSc)
Dr. Sharukh D. Shroff
Rheumatology
Advanced in Systemic Sclerosis (SSc)
Dr. Sharukh D. Shroff
Rheumatology

Spectrum Medical Inc

109 Bridge St, Apt 300, 
Danville, VA 
 (41.7 miles away)
434-793-4711
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sharukh Shroff is a Rheumatologist in Danville, Virginia. Dr. Shroff is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren Syndrome, and Discoid Lupus Erythematosus (DLE). Dr. Shroff is currently accepting new patients.

Advanced in Systemic Sclerosis (SSc)
Dr. Nicole M. Orzechowski
Rheumatology
Advanced in Systemic Sclerosis (SSc)
Dr. Nicole M. Orzechowski
Rheumatology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (44.7 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nicole Orzechowski is a Rheumatologist in Chapel Hill, North Carolina. Dr. Orzechowski is rated as an Advanced provider by MediFind in the treatment of Systemic Sclerosis (SSc). Her top areas of expertise are Temporal Arteritis, Juvenile Temporal Arteritis, Giant Cell Arteritis (GCA), and Necrotizing Vasculitis. Dr. Orzechowski is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Syed's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile